DeepMed Research

ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: ABT-072

First Posted Date: 2009-07-28

Last Posted Date: 2010-10-21

Lead Sponsor: Abbott

Target Recruit Count: 18

Registration Number: NCT00947440

Locations: 🇺🇸
Site Reference ID/Investigator# 22384, Waukegan, Illinois, United States

Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain

Phase 1

Completed

Conditions: Osteoarthritis, Knee

Interventions: Biological: PG110
Biological: Placebo

First Posted Date: 2009-07-20

Last Posted Date: 2011-06-07

Lead Sponsor: Abbott

Target Recruit Count: 56

Registration Number: NCT00941746

Locations: 🇳🇱
Site Ref # / Investigator 51568, Utrecht, Netherlands

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: ABT-450
Drug: Placebo for ABT-450
Drug: Placebo for ritonavir
Drug: ritonavir

First Posted Date: 2009-07-02

Last Posted Date: 2010-10-13

Lead Sponsor: Abbott

Target Recruit Count: 38

Registration Number: NCT00931281

Locations: 🇺🇸
Site Reference ID/Investigator# 18161, Waukegan, Illinois, United States

A Study of Single Dose of ABT-333 in Healthy Male Adults

Phase 1

Completed

Conditions: HCV Infections

Interventions: Drug: Placebo
Drug: ABT-333

First Posted Date: 2009-06-12

Last Posted Date: 2010-10-25

Lead Sponsor: Abbott

Target Recruit Count: 39

Registration Number: NCT00919490

Locations: 🇯🇵
Site Reference ID/Investigator# 19102, Kagoshima, Japan

Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimen

Phase 2

Withdrawn

Conditions: B-cell Chronic Lymphocytic Leukemia

Interventions: Drug: ABT-263

First Posted Date: 2009-06-11

Last Posted Date: 2010-02-26

Lead Sponsor: Abbott

Target Recruit Count: 150

Registration Number: NCT00918450

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Phase 2

Completed

Conditions: Hidradenitis Suppurativa

Interventions: Biological: adalimumab
Drug: Placebo

First Posted Date: 2009-06-11

Last Posted Date: 2011-05-09

Lead Sponsor: Abbott

Target Recruit Count: 154

Registration Number: NCT00918255

Locations: 🇳🇱
Site Ref # / Investigator 18470, Amsterdam, Netherlands
🇺🇸
Site Ref # / Investigator 18209, Atlanta, Georgia, United States
🇩🇰
Site Ref # / Investigator 18683, Copenhagen NV, Denmark

and more 23 locations

Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ABT-126
Drug: Placebo

First Posted Date: 2009-06-03

Last Posted Date: 2010-11-02

Lead Sponsor: Abbott

Target Recruit Count: 10

Registration Number: NCT00912431

Locations: 🇺🇸
Site Reference ID/Investigator# 20761, Glendale, California, United States

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: ABT-333
Drug: Placebo

First Posted Date: 2009-05-28

Last Posted Date: 2010-10-13

Lead Sponsor: Abbott

Target Recruit Count: 24

Registration Number: NCT00909636

Locations: 🇺🇸
Site Reference ID/Investigator# 20081, Waukegan, Illinois, United States

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: ABT-450
Drug: ritonavir

First Posted Date: 2009-05-28

Last Posted Date: 2010-10-13

Lead Sponsor: Abbott

Target Recruit Count: 8

Registration Number: NCT00909311

Locations: 🇺🇸
Site Reference ID/Investigator# 19421, Waukegan, Illinois, United States

Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy Volunteers

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: ABT-333 Tablet
Drug: ABT-333 Capsule
Drug: Placebo

First Posted Date: 2009-05-08

Last Posted Date: 2010-10-13

Lead Sponsor: Abbott

Target Recruit Count: 34

Registration Number: NCT00895102

Locations: 🇺🇸
Site Reference ID/Investigator# 19441, Waukegan, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy